BioSpace News Archive

Cocrystal Pharma, Inc. announces that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s common stock.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 50,000 shares of Akebia’s common stock on September 30, 2022, as inducements material to each such employee entering into employment with Akebia.

CooperCompanies announced that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022.

OpGen, Inc. announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 9,660,000 shares of the Company’s common stock, 33,810 shares of Series C mirroring preferred stock and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 9,660,000 shares of common stock, at a purchase price of $0.35 per share of common stock.

Nuvectis Pharma, Inc. announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference.

Inhibrx, Inc. announced that it will host a live webcast presentation on Tuesday, October 4, 2022 at 5:30 a.m. PT to announce the regulatory pathway for INBRX-101 for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD.

ImmunoGen, Inc. announced that on September 30, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 1,067,850 shares of its common stock to thirty-seven new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.

Ligand Pharmaceuticals Incorporated announced that on October 3, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 10,770 shares of its common stock to two non-executive employees in connection with their commencement of employment under the Ligand Pharmaceuticals Incorporated 2022 Employee Inducement Plan.

Summit Therapeutics Inc. announced that Dr. Robert Booth, PhD, has been appointed to its Board of Directors, effective immediately.

Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Ariadne Jerue, who joined Oncternal as Associate Director, Clinical Operations.